Clarify the issue
Review evidence, processes, and constraints before deciding what actually needs to change.
Consulting& Advisory
I work with pharmaceutical organisations and professional teams that need experienced technical review, quality-system support, facility improvement, and applied capacity building. Learn from someone who has carried the responsibility, not just studied it.

QMS, documentation, CAPA, change control, inspection readiness.
GMP upgrades, process optimisation, and facility development.
Independent review of products, processes, and documentation.
Focused training that builds lasting capability within the team.
Experience applied where it matters: quality systems, regulatory affairs, and the day-to-day realities of manufacturing.
Quality systems
Review and strengthening of pharmaceutical quality management systems: documentation structure, deviation and CAPA handling, change control, self-inspection, supplier qualification, and readiness for a regulatory inspection. The test of a system is whether staff use it without being told to.

The aim is to leave the system clearer, stronger, and easier for the internal team to sustain.
Review evidence, processes, and constraints before deciding what actually needs to change.
Translate findings into workable improvements, clear priorities, and implementation steps.
Support the people who will carry the improvements forward once the engagement ends.
Current engagement
I serve as an independent consultant with PharmaQ Limited Consultancy, a Nairobi-based institute advancing pharmaceutical quality systems across Africa. My contribution draws on experience in pharmaceutical quality management systems, manufacturing, regulatory affairs, training, and facility improvement.
Assignments begin with the organisation’s context, the technical issue that needs attention, and the capability required for improvements to last.

Poor quality carries real risk, and the cost of meeting GMP is what stands between a patient and an unsafe medicine. Good technical advice makes that investment go further.
Sector experience
Beyond company engagements, I have developed Kenya’s pharmaceutical sector investment profile with PIGA–ITC at the United Nations, and studied partnerships to improve access to quality essential medicines in East Africa with SGCI and IDRC.

Sector advisory work
Led the development of Kenya’s pharmaceutical sector investment profile to inform policy, attract responsible investment, and strengthen local manufacturing. The profile analysed market potential, the regulatory environment, value-chain gaps, and investment opportunities to support sector growth and competitiveness.
Pharmaceuticals Investment Profile Kenya (2020)WO Wanyanga, S Vugigi, F Keter
The Scinnovent Centre
2020
WO Wanyanga, SK Vugigi, FK Keter
The Scinnovent Centre
2020
WO Wanyanga, SK Vugigi, FK Keter
The Scinnovent Centre
2020
WO Wanyanga, S Vugigi, F Keter
The Scinnovent Centre
2020
S Vugigi, W Wanyanga, FK Keter
The Scinnovent Centre
2019
M Bolo, J Byaruhanga, S Vugigi, W Wanyanga, W Ronoh
The Scinnovent Centre
2016
M Bolo, J Byaruhanga, S Vugigi, W Wanyanga, W Ronoh
The Scinnovent Centre
2016
Pharmaceutical manufacturers, regulatory and health institutions, development partners, professional bodies, and academic institutions building technical capability.
Share the context, the support you need, and the outcome you are working toward. I will respond with the most useful next step.